Highlights

• Holista has a global reach with its rich line-up of proven products sold around the world.
• The year 2021 saw the company’s revenue jump 13% to hit record levels.
• The company has a positive outlook with multiple growth opportunities across all its divisions in 2022.

Holista Colltech Limited (ASX:HCT) is one of the prominent Australian players in the US$4.5 trillion global health & wellness industry. The company has four key divisions, including health supplements, ovine collagen, infection control, and food ingredients. The company caters to customers in Asia, US and Australia.

The research-driven biotech company pulled off magnificent growth across business divisions in the fiscal year 2021, strengthening the foundation for a stronger 2022.

During FY21, revenue grew 13% to a record high of AU$8 million. Moreover, the period ended 31 Decemeber 2021 saw signifcant developemnts across divisons.

Know more: Record full-year revenue powers Holista Colltech’s (ASX:HCT) bullish 2022 outlook  

A quick glance at key milestones of FY21

Info source: Company announcement

Last year, Holista inked a collaboration term sheet with Malaysian conglomerate Berjaya Corporation Berhad’s Country Farms Sdn Bhd to develop healthy food products for popular franchises in the country.

Also, the company secured trademark approval for its Natshield™ sanitiser brand in China last September, making its way to expand market for its infection controlling solution there.

Another major highlight of FY21 was Holista securing approval from Malaysian authorities to sell SARS-CoV-2 rapid test kits in the country. It also secured its first order for the kits and is in the process of obtaining regulatory approval to sell the kits in several South American countries.

Moreover, the company entered into a distribution agreement through Mutiara to sell its unique ovine collagen product to Chinese state-owned enterprise, Guangzhou Sinbio Cosmetic Co Ltd. The agreement will be effective only after the successful completion of certain trials and Chinese regulatory approvals.

As per the agreement, Sinbio will buy Holista’s annual production capacity of 48 tons from its Western Australian plant during the first year of the deal. The order will scale up to 144 tons in the second year, 288 tons in the third year, and 576 tons in the fourth and fifth years.

Must Watch: Holista Colltech ASX HCT guides for strong 2022, what’s driving this bullish outlook?

Holista clenching top-drawer ranks in the industry

With years of experience and specialisation in making innovative herbs and natural products, the company has created ingredients which do not compromise on taste, odour, or mouthfeel. Some of its market-leading products include low-Glycemic Index (GI) bread, noodles/pasta and flatbreads as well as a low-calorie/Low-GI sugar substitute.

Also, the company offers a wide array of all-natural, non-toxic and effective sanitisers for consumers as well as industrial applications within its product portfolio.

Significantly, Holista is the sole company in the world developing ovine collagen from disease-free Australian sheep using patented extraction methods. The company has emerged as a leader in Malaysia for the distribution of natural health supplements.

Related Read: Which health & wellness trends are paving success path for Holista Colltech (ASX:HCT)?

Holista believes that it is well-positioned for 2022 and beyond with multiple growth avenues with defensive revenue streams.

Opportunities across divisions (Data source: HCT annual report)

Considering the large addressable and growing markets in health & wellness, the company aims to expand its global reach with proven products being sold around the world. Holista’s well-established partnerships with leading global customers paint a positive outlook as well as bright prospects for FY22.

HCT traded at AU$0.034 on 31 March 2022, up 3.030% on the ASX.